表纸
市场调查报告书

市场焦点:何杰金氏淋巴瘤

Market Spotlight: Hodgkin's Lymphoma

出版商 Datamonitor Healthcare 商品编码 939992
出版日期 内容资讯 英文 41 Pages
商品交期: 最快1-2个工作天内
价格
市场焦点:何杰金氏淋巴瘤 Market Spotlight: Hodgkin's Lymphoma
出版日期: 2020年08月10日内容资讯: 英文 41 Pages
简介

本报告提供全球何杰金氏淋巴瘤相关市场调查,提供疾病的背景,治疗方法,流行病学,上市的医药品,开发平台上的医药品,药事法规方面的重要动向,授权与资产收购,本源专利,商机,临床试验状况等资讯,再加上分析师和意见领袖的意见等资讯。

目录

概要

主要调查结果

疾病的背景

  • 亚类型

治疗方法

  • 化疗
  • 放射治疗
  • 免疫疗法
  • 干细胞移植(SCT)

流行病学

上市的医药品

开发平台上的医药品

最新趋势分析师的意见

  • Keytruda(2020年3月2日)
  • Folotyn(2019年1月17日)

今后主要的动向

法规方面主要的动向

  • 标准审查

成功的可能性

许可和资产收购协议

  • BeiGene在Bristol / Celgene合并之前收购Tislelizumab

本源专利

商机

临床试验情势

  • 各阶段的临床试验赞助者
  • 各期的临床试验赞助者

参考文献

  • 处方药相关资讯

附录

目录
Product Code: DMKC0185142

This Market Spotlight report covers the Hodgkin's Lymphoma market, comprising key marketed and pipeline drugs, clinical trials, key upcoming and regulatory events, recent events and analyst opinion, patent information, a 10-year disease incidence forecast, probability of success, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

Datamonitor Healthcare estimates that in 2019, there were 80,800 incident cases of Hodgkin's lymphoma worldwide, and expects that number to increase to 86,500 incident cases by 2028. * In the same year, there were approximately 277,600 five-year prevalent cases of Hodgkin's lymphoma worldwide, which is expected to increase to 295,000 five-year prevalent cases by 2028.

The approved drugs in the Hodgkin's lymphoma space target antibody-drug conjugate, cluster of differentiation 30/tumor necrosis factor receptor superfamily member 8, microtubules, DNA, the immune system, and programmed death-1 receptor/programmed death ligands. The majority of the approved drugs are administered via the intravenous route.

The majority of the industry-sponsored drugs in active clinical development for Hodgkin's lymphoma are in Phase II, with no drugs in Phase III.

Therapies in the pipeline for Hodgkin's lymphoma focus on a wide variety of targets. The majority of the pipeline drugs in development are administered via the intravenous route, with the remainder being tested in oral, intratumoral, and subcutaneous formulations.

The only high-impact upcoming event for drugs in the Hodgkin's lymphoma space is topline Phase II trial results for ADCT-301. The overall likelihood of approval of a Phase I hematologic asset is 9.9%, and the average probability a drug advances from Phase III is 61.4%. Drugs, on average, take 9.1 years from Phase I to approval, compared to 9.4 years in the overall oncology space.

The distribution of clinical trials across Phase I-IV indicates that the vast majority of trials for Hodgkin's lymphoma have been in the early and mid-phases of development, with 93% of trials in Phase I-II, and only 7% in Phase III-IV.

The US has a substantial lead in the number of Hodgkin's lymphoma clinical trials globally. France leads the major European markets, while China has the top spot in Asia.

Clinical trial activity in the Hodgkin's lymphoma space is dominated by completed trials. Takeda has the highest number of completed clinical trials for Hodgkin's lymphoma, with 50 trials.

Takeda leads industry sponsors with the highest overall number of clinical trials for Hodgkin's lymphoma, followed by Bristol Myers Squibb.

TABLE OF CONTENTS

CONTENTS

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

  • Subtypes

TREATMENT

  • Chemotherapy
  • Radiation therapy
  • Immunotherapy
  • Stem cell transplantation (SCT)

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

  • Keytruda for Hodgkin's Lymphoma (May 13, 2020)
  • Keytruda for Hodgkin's Lymphoma (March 2, 2020)
  • Folotyn for Hodgkin's Lymphoma (January 17, 2019)

KEY UPCOMING EVENTS

KEY REGULATORY EVENTS

  • New Approvals, Biosecurity In Spotlight As China Gears For National Congress
  • A Slew Of Standard Reviews

PROBABILITY OF SUCCESS

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase

BIBLIOGRAPHY

  • Prescription information

APPENDIX

LIST OF FIGURES

  • Figure 1: Trends in incident cases of Hodgkin's lymphoma, 2019-28
  • Figure 2: Overview of pipeline drugs for Hodgkin's lymphoma in the US
  • Figure 3: Pipeline drugs for Hodgkin's lymphoma, by company
  • Figure 4: Pipeline drugs for Hodgkin's lymphoma, by drug type
  • Figure 5: Pipeline drugs for Hodgkin's lymphoma, by classification
  • Figure 6: Keytruda for Hodgkin's Lymphoma (May 13, 2020): Phase III - KEYNOTE-204
  • Figure 7: Keytruda for Hodgkin's Lymphoma (March 2, 2020): Phase III - KEYNOTE-204
  • Figure 8: Key upcoming events in Hodgkin's lymphoma
  • Figure 9: Probability of success in the Hodgkin's lymphoma pipeline
  • Figure 10: Clinical trials in Hodgkin's lymphoma
  • Figure 11: Top 10 drugs for clinical trials in Hodgkin's lymphoma
  • Figure 12: Top 10 companies for clinical trials in Hodgkin's lymphoma
  • Figure 13: Trial locations in Hodgkin's lymphoma
  • Figure 14: Hodgkin's lymphoma trials status
  • Figure 15: Hodgkin's lymphoma trials sponsors, by phase

LIST OF TABLES

  • Table 1: Incident cases of Hodgkin's lymphoma, 2019-28
  • Table 2: Five-year prevalent cases of Hodgkin's lymphoma, 2019-28
  • Table 3: Marketed drugs for Hodgkin's lymphoma
  • Table 4: Pipeline drugs for Hodgkin's lymphoma in the US
  • Table 5: Keytruda for Hodgkin's Lymphoma (May 13, 2020)
  • Table 6: Keytruda for Hodgkin's Lymphoma (March 2, 2020)
  • Table 7: Folotyn for Hodgkin's Lymphoma (January 17, 2019)
  • Table 8: Historical global sales, by drug ($m), 2015-19
  • Table 9: Forecasted global sales, by drug ($m), 2020-24